Biopsy Needles Market Research Report, Analysis and Forecast – (2021 – 2028)

Rising Cancer Incidence Driving the Biopsy Needles Market 

The Biopsy Needles Market is undergoing a significant transformation, propelled primarily by the rising global incidence of cancer. For instance, global cancer cases reached 19.3 million in 2022 and are projected to cross 24 million by 2030. This rise in diagnosis requirements is directly impacting the demand for biopsy needles, which are critical for obtaining tissue samples. Notably, breast, prostate, lung, and colorectal cancers are among the most frequently diagnosed types, each necessitating precise histological evaluation using biopsy needles. 

Such growth in diagnostic cases is influencing hospitals, diagnostic centers, and specialty clinics to upgrade their oncology departments with advanced biopsy instruments. In turn, this contributes to both volume expansion and technological innovation within the Biopsy Needles Market. 

Technological Advancements Elevating the Biopsy Needles Market 

The Biopsy Needles Market is witnessing a wave of innovation driven by the need for greater precision, patient comfort, and diagnostic accuracy. For example, vacuum-assisted biopsy needles and automated core needle biopsy systems are being adopted widely in developed markets, reducing the need for surgical biopsies and offering minimally invasive alternatives. These technologies enable larger sample extraction in fewer insertions, increasing diagnostic efficiency. 

Furthermore, the emergence of image-guided biopsy systems, such as those assisted by MRI, CT, or ultrasound, has elevated the demand for compatible biopsy needles. These devices reduce procedural time, enhance targeting precision, and increase diagnostic yield, thereby intensifying competition and fostering product diversification in the Biopsy Needles Market. 

Shift Toward Minimally Invasive Procedures Expanding the Biopsy Needles Market 

Healthcare providers are increasingly prioritizing patient-centric approaches, which has led to the rapid adoption of minimally invasive biopsy techniques. This shift is directly influencing the growth trajectory of the Biopsy Needles Market. For instance, core needle biopsies and fine needle aspiration biopsies (FNAB) have largely replaced open surgical biopsies for initial diagnosis in various cancers and organ-specific conditions. 

The benefits of reduced patient trauma, lower infection risk, shorter hospital stays, and cost savings are driving both patients and clinicians to prefer needle-based diagnostics. This trend is particularly evident in outpatient settings and ambulatory surgical centers, where procedure volumes for minimally invasive biopsies are steadily rising. 

Biopsy Needles Market Size Poised for Robust Expansion 

The Biopsy Needles Market Size was estimated at over USD 800 million in 2023 and is anticipated to exceed USD 1.3 billion by 2030, driven by rising procedure volumes and increased healthcare investments in diagnostic technologies. The CAGR is expected to remain in the high single digits through the forecast period, fueled by the aforementioned demand and supply-side drivers. 

Such growth projections are further supported by strategic expansions from leading market players into emerging markets in Asia-Pacific and Latin America, where infrastructure upgrades are enabling the penetration of advanced biopsy solutions. 

Aging Population Accelerating Demand in Biopsy Needles Market 

The aging global population is a key demographic trend underpinning the long-term growth of the Biopsy Needles Market. Individuals aged 65 and above represent the fastest-growing segment of the population, and this group faces higher risks of chronic diseases, especially cancer. For instance, nearly 60% of cancer diagnoses occur in individuals over 60 years of age. 

This demographic shift is significantly increasing the volume of diagnostic interventions, particularly in oncology and hepatology, where biopsy needles play a vital role. Consequently, long-term care facilities, oncology clinics, and specialty hospitals are bolstering their diagnostic capabilities with high-precision biopsy systems. 

Biopsy Needles Market Benefiting from Rising Chronic Liver Disease Cases 

The rising prevalence of chronic liver conditions, such as nonalcoholic fatty liver disease (NAFLD), cirrhosis, and hepatitis C, is fueling the expansion of the Biopsy Needles Market. Liver biopsy remains the gold standard for assessing fibrosis and inflammation levels. In 2024 alone, over 1.5 billion people globally were affected by liver-related ailments, many of which required histopathological analysis. 

Fine needle aspiration and core needle biopsy methods are increasingly deployed to evaluate liver masses and guide treatment pathways. This has created substantial demand for liver-specific biopsy needles and is pushing manufacturers to introduce specialized solutions tailored for hepatology. 

Strategic Healthcare Investments Driving Biopsy Needles Market Penetration 

Global healthcare systems are ramping up investments in diagnostic infrastructure, which is positively impacting the Biopsy Needles Market. For instance, national cancer control programs in countries such as India, Brazil, and China are integrating early detection protocols that include image-guided needle biopsies. These policy-driven expansions are enabling public hospitals and regional diagnostic labs to procure and utilize biopsy needle systems more effectively. 

Simultaneously, private sector investments in outpatient diagnostic chains and multispecialty clinics are contributing to growing procurement volumes of biopsy devices. These investments not only drive unit sales but also lead to recurring demand for disposable biopsy needles. 

Biopsy Needles Market Advancing with Personalized Medicine Trends 

The Biopsy Needles Market is closely aligned with the evolution of personalized medicine and molecular diagnostics. Tissue biopsies provide the foundational samples for gene profiling, tumor marker analysis, and other advanced tests used to tailor treatments. For instance, in breast and lung cancers, HER2 and EGFR testing requires precise sample collection, often achievable only through high-quality biopsy needles. 

As precision oncology gains traction, especially in North America and Europe, the need for efficient, safe, and versatile biopsy needle systems becomes paramount. This shift is prompting R&D in next-generation biopsy devices capable of preserving sample integrity for genetic analysis. 

Increasing Adoption in Ambulatory Care Settings Reshaping Biopsy Needles Market 

Ambulatory care centers are emerging as a significant distribution channel within the Biopsy Needles Market, owing to their ability to conduct same-day diagnostic procedures. For example, in the United States alone, more than 60% of non-emergency biopsies are now being performed in outpatient settings. 

This migration is not only reducing the procedural cost burden on tertiary hospitals but also enhancing patient accessibility to advanced diagnostics. As a result, device manufacturers are targeting this segment with portable, easy-to-use biopsy kits that meet the operational and regulatory requirements of ambulatory clinics. 

Biopsy Needles Market Size Strengthened by Public Awareness and Screening Programs 

Enhanced public awareness campaigns and national screening initiatives are contributing to the increased utilization of biopsy procedures, thereby supporting the expansion of the Biopsy Needles Market Size. For instance, routine mammography screening often identifies suspicious lesions that require biopsy confirmation, driving the demand for breast biopsy needles. 

Countries like the UK, Japan, and Australia have robust cancer screening frameworks that regularly refer patients for biopsy procedures. These programs not only aid early detection but also ensure a steady demand cycle for needle-based diagnostics. 

Conclusion: Biopsy Needles Market Positioned for Dynamic Evolution 

In conclusion, the Biopsy Needles Market is set to witness dynamic growth over the coming years, influenced by a synergistic mix of demographic trends, technological advancements, expanding application areas, and supportive healthcare policies. As diagnostic requirements grow in complexity and volume, the demand for reliable, minimally invasive, and technologically advanced biopsy needle systems will intensify. 

Device manufacturers and healthcare providers who align with these trends are poised to capitalize on emerging opportunities in both mature and developing markets. The ongoing evolution of healthcare delivery—toward faster, safer, and more personalized care—positions the Biopsy Needles Market at the center of modern diagnostic innovation. 

 

“Track Country-wise Biopsy Needles Production and Demand through our Database”

• • • Biopsy Needles sales volume database for 29+ countries worldwide

Regional Dynamics Fueling Growth in the Biopsy Needles Market 

The Biopsy Needles Market is witnessing diverse growth trajectories across various geographies, influenced by differing healthcare priorities, population structures, and diagnostic capabilities. North America continues to dominate the global landscape, driven by a mature healthcare infrastructure, widespread adoption of advanced diagnostic techniques, and a high burden of cancer. For instance, over 1.9 million new cancer cases were reported in the United States in 2023, with breast and prostate cancers being the most common—both of which frequently require core and fine needle biopsies for diagnosis. 

In Europe, markets like Germany, France, and the UK are experiencing steady demand, bolstered by government-supported cancer screening programs and increasing public awareness. Countries in the Nordic region are also notable for their early adoption of minimally invasive technologies, further propelling the Biopsy Needles Market. 

Asia-Pacific presents the most dynamic growth opportunities. Nations like China and India are witnessing double-digit growth rates due to rising cancer prevalence, increasing investments in healthcare infrastructure, and a shift from traditional diagnostic methods to modern imaging-guided biopsy procedures. For example, India recorded a 20% year-on-year increase in image-guided biopsies across urban hospitals, which directly boosts the regional share of the Biopsy Needles Market. 

Latin America and the Middle East are gradually emerging, with Brazil, Mexico, and Saudi Arabia leading demand. While infrastructure gaps remain, growing private sector investments in diagnostic services and improving access to healthcare are translating into expanded demand for biopsy needle procedures. 

Biopsy Needles Market Shaped by Decentralized and Regional Manufacturing Hubs 

Biopsy Needles Manufacturing is becoming increasingly decentralized, aligning with broader trends in medical device production and regional supply resilience. Previously concentrated in North America and Europe, manufacturing operations are now expanding into Asia-Pacific to leverage lower production costs, proximity to growing markets, and favorable regulatory frameworks. Countries such as China, Malaysia, and South Korea are strengthening their role as manufacturing hubs by offering cost-effective production and streamlined regulatory approvals. 

For instance, several leading manufacturers have established ISO-certified Biopsy Needles Manufacturing facilities in Shanghai and Penang, aimed at serving both domestic and export markets. These facilities are equipped with advanced CNC machining, robotic assembly lines, and sterile packaging technologies, enabling high-volume, precision-oriented production. 

Biopsy Needles Manufacturing is also increasingly incorporating automation and quality control technologies, such as AI-assisted visual inspection and laser calibration, to enhance consistency and compliance with stringent clinical safety standards. Manufacturers focused on export-oriented strategies are integrating lean production and Six Sigma practices to reduce waste and increase output efficiency. This evolution in manufacturing sophistication is positioning select companies for greater competitiveness in the global Biopsy Needles Market. 

Segmentation of the Biopsy Needles Market by Product Type 

The Biopsy Needles Market is segmented by product type into core needle biopsy (CNB), fine needle aspiration biopsy (FNAB), and vacuum-assisted biopsy (VAB). Each segment caters to specific clinical needs and application areas. Among these, core needle biopsy holds the largest market share, supported by its broad application in breast, prostate, and lung biopsies. For instance, CNB accounts for over 60% of total biopsy procedures performed in oncology due to its ability to extract sufficient tissue volume for accurate histopathology. 

Fine needle aspiration biopsy continues to be favored in cytological investigations, particularly for thyroid, lymph nodes, and superficial lesions. Its minimally invasive nature and lower complication risk make it ideal for outpatient settings and primary care facilities. The demand for FNAB devices is notably rising in emerging markets, where lower-cost diagnostic tools are prioritized. 

Vacuum-assisted biopsy, while currently occupying a smaller share, is gaining traction rapidly, particularly in breast cancer diagnostics. These systems enable multiple tissue samples with a single insertion, reducing patient discomfort and improving accuracy. As device costs decrease and practitioner familiarity increases, vacuum-assisted biopsy is expected to significantly expand its footprint in the Biopsy Needles Market. 

Biopsy Needles Market Segmentation by Application Area 

Application-based segmentation in the Biopsy Needles Market reveals oncology as the most dominant category. Biopsy needles are extensively used for tumor diagnosis, grading, and staging across a wide range of cancers. Breast cancer alone accounts for nearly 25% of all biopsy needle usage globally, driven by organized screening programs and rising awareness among women regarding early detection. 

Hematology and musculoskeletal diagnostics represent emerging application areas. For example, bone marrow biopsies using specialized core biopsy needles are critical for diagnosing blood cancers and marrow disorders. Musculoskeletal applications, including joint and bone lesion biopsies, are also growing, particularly in aging populations where orthopedic complications are rising. 

Liver biopsy continues to be an essential application segment, especially given the increase in chronic liver diseases such as NAFLD. Hospitals are deploying dedicated liver biopsy kits integrated with ultrasound guidance to ensure procedural safety. These application-specific needs are driving manufacturers to diversify their product lines, contributing to higher segmental specialization within the Biopsy Needles Market. 

End-User Segmentation in the Biopsy Needles Market 

End-users in the Biopsy Needles Market include hospitals, diagnostic centers, and ambulatory surgical centers. Hospitals remain the largest end-user group, accounting for over 55% of global demand due to their comprehensive diagnostic setups and capacity to handle complex cases. For example, tertiary hospitals often have multidisciplinary tumor boards that rely heavily on biopsy diagnostics for treatment planning. 

Diagnostic centers are witnessing strong demand growth, particularly in urban and suburban locations. These centers cater to high-volume, rapid-turnaround biopsy procedures such as FNAB for thyroid and breast masses. The trend toward outsourcing diagnostic services is also pushing this segment forward. 

Ambulatory surgical centers are becoming increasingly relevant, especially in North America and Western Europe, where healthcare cost containment is a key priority. These centers offer same-day biopsy procedures, lowering costs while maintaining diagnostic accuracy. Manufacturers targeting this segment are focusing on compact, disposable, and easy-to-use biopsy kits optimized for high throughput. 

Price Trend Analysis in the Biopsy Needles Market 

Pricing dynamics in the Biopsy Needles Market are shaped by a blend of material cost, technology integration, regulatory compliance, and competitive pressure. Standard core and fine needle biopsy devices are experiencing moderate pricing pressures due to increasing commoditization and bulk procurement by hospital chains. For instance, the average unit price for core needle biopsy devices has declined by 5% over the last three years in high-volume markets like the United States and India. 

In contrast, specialized biopsy systems such as vacuum-assisted and image-guided biopsy needles command premium pricing. These products often integrate advanced features like ergonomic grips, depth control, and compatibility with imaging systems, justifying a 20–30% price differential compared to traditional biopsy needles. However, prices are expected to stabilize as these technologies mature and production volumes increase. 

Biopsy Needles Manufacturing cost trends are also evolving. The use of advanced polymers, stainless steel composites, and silicone-based coatings improves product performance but also adds to cost. Manufacturers are balancing material quality with cost efficiency through automation and economies of scale. For example, high-capacity production lines in Southeast Asia have helped reduce manufacturing costs by up to 15%, enhancing price competitiveness globally. 

Biopsy Needles Market Influenced by Procurement and Reimbursement Patterns 

Another layer influencing the Biopsy Needles Market is the procurement strategy and reimbursement framework in different regions. Institutional bulk purchases and tender-based procurement, particularly in public healthcare systems, are favoring suppliers who offer bundled services and value-added features such as training and after-sales support. These practices are compressing margins in certain regions but expanding overall volumes. 

Reimbursement policies also play a decisive role. In countries where biopsy procedures are fully reimbursed, such as Germany and Japan, there is a higher adoption of premium biopsy systems. On the contrary, in regions with out-of-pocket payment models, such as parts of Africa and Southeast Asia, affordability significantly influences device selection. This divergence necessitates region-specific pricing and marketing strategies from players operating in the Biopsy Needles Market. 

 A Regionally Diversified and Technologically Evolving Biopsy Needles Market 

The Biopsy Needles Market is evolving into a regionally diversified and technologically stratified ecosystem. From highly advanced biopsy systems used in developed markets to cost-efficient diagnostic tools gaining traction in developing economies, the market is defined by its responsiveness to local demand, regulatory conditions, and care delivery models. Biopsy Needles Manufacturing strategies are shifting accordingly, becoming more agile, decentralized, and quality-centric. 

As segmentation deepens and end-user profiles diversify, market players that align product innovation with regional demand dynamics are likely to secure competitive advantages. Price, performance, application specificity, and supply chain resilience will remain the critical differentiators in the next phase of growth for the global Biopsy Needles Market. 

 

“Biopsy Needles Manufacturing Database”

• • • Biopsy Needles top manufacturers market share for 29+ manufacturers
    • Top 9 manufacturers and top 19 manufacturers of Biopsy Needles in North America, Europe, Asia Pacific
    • Biopsy Needles sales dashboard, Biopsy Needles sales data in excel format

Top Manufacturers Dominating the Biopsy Needles Market 

The Biopsy Needles Market is led by a concentrated group of manufacturers who continue to drive innovation, enhance procedural accuracy, and expand their global footprint. These companies are shaping industry standards through robust portfolios and regionally tailored strategies. 

Becton, Dickinson and Company is among the foremost players in the global Biopsy Needles Market. With product lines such as BD Vacora™, BD Temno™, and BD Achieve™, the company delivers both manual and vacuum-assisted biopsy systems. Its offerings are widely used in core needle biopsy procedures and soft tissue sampling. 

Medtronic has expanded its reach in the market by integrating biopsy technology into its minimally invasive product segment. The company’s biopsy devices are designed for precision targeting and ergonomic use, serving interventional radiology, oncology, and gastroenterology departments globally. 

Hologic holds a dominant position, particularly in breast biopsy systems. The company’s signature products, ATEC® and Eviva®, are well-established in stereotactic and vacuum-assisted breast biopsies. These devices are integral in outpatient imaging centers and breast care clinics. 

Olympus plays a strong role in endoscopic biopsy procedures. Its line of fine needle aspiration products, particularly those used in EUS-FNA, is widely adopted across gastrointestinal endoscopy practices. These needles are engineered to provide better sampling efficiency while reducing procedural complexity. 

Argon Medical Devices has established itself with a focus on percutaneous soft tissue biopsy. Products such as Tru-Core™ II and Pro-Mag™ Ultra offer robust performance in both hospital and outpatient settings. The company is recognized for its cost-effective and reliable solutions. 

Cook Medical offers one of the most versatile biopsy needle portfolios. Its Quick-Core® and EchoTip® biopsy products are commonly used in liver, kidney, and pancreatic biopsies, often integrated with image-guided procedures. Cook’s emphasis on ultrasound-compatible designs has given it a competitive edge in complex diagnostic environments. 

Cardinal Health continues to be a significant player in the Biopsy Needles Market by supplying standardized, high-volume disposable biopsy products. The company’s wide distribution network allows it to efficiently cater to both public and private healthcare institutions, especially in North America. 

Boston Scientific supports biopsy procedures within interventional oncology, offering needle-based solutions aligned with tumor ablation and localization technologies. The company’s expansion into precision-targeting systems for solid tumor diagnostics supports its niche within the market. 

Fujifilm Medical Systems has been strengthening its presence in the biopsy space by integrating biopsy needle technology with advanced imaging modalities. Its solutions are increasingly used in gastroenterology and pulmonology, where real-time visualization is critical for accurate tissue sampling. 

INRAD Inc., while a smaller player, is known for producing high-quality specialized biopsy needles tailored for customized medical applications. The company addresses niche market requirements, especially in orthopedic and urology segments. 

 

Biopsy Needles Market Share by Leading Manufacturers 

The global Biopsy Needles Market is moderately consolidated, with the top five manufacturers accounting for a substantial portion of total market share. Becton, Dickinson and Company leads with a sizable global presence and extensive product lines, capturing an estimated 20–25% of market share. 

Hologic holds a strong position in the breast biopsy segment and represents 12–15% of the total market share, primarily in North America and parts of Europe. Medtronic’s footprint continues to grow across minimally invasive diagnostic procedures, with an estimated share of 10–12%, driven by its ability to integrate biopsy devices into broader surgical systems. 

Olympus maintains 8–10% of global share, supported by its dominance in endoscopic biopsy tools and FNA systems. Argon Medical and Cook Medical collectively represent around 10% of the market, with strong positioning in soft tissue and image-guided biopsy solutions. The rest of the market is divided among regional players, emerging manufacturers, and niche solution providers who serve local procurement networks and specific specialty applications. 

 

Biopsy Needle Product Differentiation Among Manufacturers 

The Biopsy Needles Market is increasingly characterized by product specialization. While traditional core and fine needle products continue to dominate in terms of volume, manufacturers are introducing innovations in design, compatibility, and usability. 

BD’s core needle biopsy systems, for example, focus on precision control and ergonomic design. Its BD Achieve™ device allows for single-handed operation, reducing procedure time and increasing physician comfort. 

Hologic’s Eviva® system features real-time imaging compatibility, designed for stereotactic procedures. The device simplifies breast tissue biopsy by integrating vacuum-assisted features with real-time lesion targeting, thereby improving clinical outcomes. 

Cook Medical’s EchoTip® technology stands out with its enhanced ultrasound visibility. This feature is critical in liver and pancreatic biopsies, where real-time guidance is necessary to avoid critical structures. 

Olympus provides biopsy needles with reinforced sheaths and adjustable tip configurations, which improve sampling success rates in endoscopic ultrasound-guided procedures. Its endoscopy-focused innovation continues to drive differentiation in gastrointestinal diagnostics. 

 

Recent Developments and Industry Movements 

Several recent developments have further shaped the trajectory of the Biopsy Needles Market: 

• In January 2024, BD announced the global expansion of its Temno Evolution™ system, targeting liver and kidney biopsy applications with improved coaxial access and sample retrieval features. 

• In March 2024, Hologic launched an upgraded version of its ATEC® Breast Biopsy System, introducing noise-reduction technology and faster tissue collection—aimed at improving patient comfort during outpatient procedures. 

• In June 2024, Argon Medical Devices introduced a redesigned Pro-Mag™ Ultra II with advanced depth control technology, enhancing procedural safety for deep soft tissue biopsies. 

• By August 2024, Fujifilm began commercial trials of its integrated biopsy and imaging platform in select Asian markets. The system combines real-time visualization with biopsy access, aiming to reduce procedure times in pulmonology departments. 

• In October 2024, Cook Medical expanded its manufacturing facility in Indiana to increase production of its Quick-Core® series, signaling strong growth in demand from both domestic and international markets. 

• A notable partnership was also announced in December 2024, where Boston Scientific entered a co-development agreement with a digital pathology startup to explore AI-guided biopsy planning, further integrating diagnostics with treatment personalization. 

“Biopsy Needles Production Data and Biopsy Needles Production Trend”

• • • Biopsy Needles sales database for historical years, 10 years historical data
    • Biopsy Needles sales data and forecast for next 7 years

Key Insights that the Biopsy Needles Market analysis report presents are:

• Biopsy Needles Market revenue and demand by countries
• Break-down of the Biopsy Needles Market in terms of application areas, target customers, and other potential market segments
• Areas that are relatively more potential and are faster growing
• Biopsy Needles Market competitive scenario, market share analysis
• Biopsy Needles Market business opportunity analysis

Global and Country-Wise Biopsy Needles Market Statistics

• Global and Country-Wise Biopsy Needles Market Size ($Million) and Forecast – (2021-2028)
• Global and Country-Wise Biopsy Needles Market Trend Analysis
• Global and Country-Wise Biopsy Needles Market Business Opportunity Assessment